Related Experiment Video
Updated: Sep 11, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48
Jiatong Xiao1,2, Jinhui Liu1,2, Chunyu Zhang3
1Xiangya Hospital Central South University, Changsha, Hunan, China.
Background:
Immune checkpoint inhibitors have shown limited response rates in bladder cancer. RC48-antibody-drug conjugate (ADC) shows potential for combination with immune checkpoint inhibitors. This study aimed to elucidate RC48-ADC's mechanism in sensitizing tumors to immunotherapy and identify optimal combination strategies.
Methods:
Bioinformatics (The Cancer Genome Atlas, GEO, Xiangya cohorts) analyzed correlations between HER2, immune markers, and therapy response. The h-HER2-MB49 and sg-PD-L1-MB49 cell line was generated. In vitro/vivo models assessed RC48-ADC's impact on the tumor immune microenvironment using flow cytometry, immunofluorescence, co-culture, chemotaxis, CUT&Tag assays, transcriptomics, and ELISA. Subcutaneous tumor models evaluated combination therapies. At the clinical level, bladder cancer immune therapy cohort tissue microarrays were used, and the aforementioned mechanisms were validated using immunohistochemistry and immunofluorescence.
Results:
HER2 expression is associated with an inhibitory tumor immune microenvironment and resistance to immunotherapy. RC48-ADC treatment can reactivate this HER2-related inhibitory tumor immune microenvironment, thereby enhancing immunotherapy effectiveness. Mechanistically, RC48-ADC reactivates the tumor immune microenvironment by reducing PD-L1 transcription via Hippo pathway activation. It also promotes the release of chemokines (CCL5, CXCL9, and CXCL14) and recruits cytotoxic T-lymphocytes. In preclinical mouse models, RC48-ADC synergized with CTLA-4 and PD-L1 antibodies.
Conclusions:
RC48-ADC enhances immunotherapy by regulating PD-L1 through the Hippo-TAZ pathway and reactivating CD8+T cells, offering a novel combination therapeutic strategy for bladder cancer.
Insights
RC48-antibody-drug conjugate (ADC) reactivates the tumor immune microenvironment by reducing PD-L1 via the Hippo pathway, enhancing immunotherapy for bladder cancer. This novel combination strategy synergizes with checkpoint inhibitors.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Immune checkpoint inhibitors (ICIs) exhibit limited efficacy in bladder cancer.
- RC48-antibody-drug conjugate (ADC) presents a promising candidate for combination therapy with ICIs.
- Understanding the synergistic mechanisms is crucial for optimizing bladder cancer treatment.
Purpose of the Study:
- To investigate the mechanism by which RC48-ADC sensitizes bladder tumors to immunotherapy.
- To identify optimal combination strategies involving RC48-ADC and ICIs.
- To elucidate the role of HER2 expression in tumor immune evasion and therapy resistance.
Main Methods:
- Bioinformatic analysis of The Cancer Genome Atlas, GEO, and Xiangya cohorts.
- In vitro and in vivo studies using MB49 cell lines and subcutaneous tumor models.
- Assessment of tumor immune microenvironment modulation via flow cytometry, transcriptomics, and ELISA.
- Clinical validation using bladder cancer tissue microarrays and immunohistochemistry.
Main Results:
- HER2 expression correlates with an immunosuppressive tumor microenvironment and immunotherapy resistance.
- RC48-ADC treatment reactivates the tumor immune microenvironment and enhances immunotherapy.
- RC48-ADC reduces PD-L1 transcription through Hippo pathway activation, promoting chemokine release and T-cell recruitment.
- RC48-ADC demonstrated synergy with CTLA-4 and PD-L1 antibodies in preclinical models.
Conclusions:
- RC48-ADC enhances immunotherapy by modulating PD-L1 via the Hippo-TAZ pathway.
- RC48-ADC reactivates CD8+ T-cells, offering a novel therapeutic strategy for bladder cancer.
- The study provides a rationale for combining RC48-ADC with immune checkpoint inhibitors in bladder cancer treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...